Gender differences in leukemia outcomes based on health care expenditures using estimates from the GLOBOCAN 2020 DOI Creative Commons
Maedeh Amini, Rajesh Sharma, Chinmay Jani

и другие.

Archives of Public Health, Год журнала: 2023, Номер 81(1)

Опубликована: Авг. 21, 2023

Abstract Background Leukemia contributes significantly to the global cancer burden. Due importance of evaluating improvements in leukemia outcomes, current study aimed examine variations mortality-to-incidence ratio (MIR) between genders and association MIR with health expenditures selected countries. Methods The incidence mortality rates were extracted from GLOBOCAN 2020 database. In total, 56 countries included based on data quality reports exclusion missing data. associations changes over time ( $$\updelta$$ δ MIR) human development index (HDI), expenditure (CHE) per capita, as a percentage gross domestic product (CHE/GDP) investigated using Spearman’s rank correlation coefficient. Results 2020, an estimated 474,519 new cases diagnosed globally, 311,594 deaths occurred due disease. Male patients exhibited higher compared females scale. Our analysis revealed that MIRs highest lowest Egypt (0.79) United States (0.29), respectively. Remarkably, greater HDI, CHE CHE/GDP tended have lower both within gender-specific subgroups. δMIR demonstrated significant negative HDI whereas no observed among female for CHE/GDP. Besides, all three indicators showed trends towards correlations males, though these not statistically p >0.05). Conclusions Generally, be most favorable (i.e., lower) high expenditure. gender differences outcomes may reflect potential influence social, material, behavioral, biological factors.

Язык: Английский

Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications DOI
Tong Xiao, Juyeun Lee, Timothy D. Gauntner

и другие.

Nature reviews. Cancer, Год журнала: 2024, Номер 24(5), С. 338 - 355

Опубликована: Апрель 8, 2024

Язык: Английский

Процитировано

22
Demographic bias in misdiagnosis by computational pathology models DOI
Anurag Vaidya, Richard J. Chen, Drew F. K. Williamson

и другие.

Nature Medicine, Год журнала: 2024, Номер 30(4), С. 1174 - 1190

Опубликована: Апрель 1, 2024

Язык: Английский

Процитировано

22
Characterising sex differences of autosomal DNA methylation in whole blood using the Illumina EPIC array DOI Creative Commons
Olivia A. Grant, Yucheng Wang, Meena Kumari

и другие.

Clinical Epigenetics, Год журнала: 2022, Номер 14(1)

Опубликована: Май 14, 2022

Sex differences are known to play a role in disease aetiology, progression and outcome. Previous studies have revealed autosomal epigenetic between males females some tissues, including DNA methylation patterns. Here, we report for the first time an analysis of sex DNAme using Illumina EPIC array human whole blood by performing discovery (n = 1171) validation 2471) analysis.We identified validated 396 sex-associated differentially methylated CpG sites (saDMPs) with majority found be female-biased CpGs (74%). These saDMP's enriched islands shores located preferentially at 5'UTRs, 3'UTRs enhancers. Additionally, 266 significant regions overlapping genes, which previously been shown exhibit differences, novel genes. Transcription factor binding site enrichment transcription factors related critical developmental processes determination such as SRY ESR1.Our study reports reliable catalogue elucidates several characteristics these large-scale data sets. This resource will benefit future aiming investigate specific signatures further our understanding blood.

Язык: Английский

Процитировано

59
The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors DOI Creative Commons
Anna Tosi,

Beatrice Parisatto,

Anna Menegaldo

и другие.

Journal of Experimental & Clinical Cancer Research, Год журнала: 2022, Номер 41(1)

Опубликована: Сен. 20, 2022

Immune checkpoint inhibitors (ICI) are approved for treatment of recurrent or metastatic oropharyngeal head and neck squamous cell carcinoma in the first- second-line settings. However, only 15-20% patients benefit from this treatment, a feature increasingly ascribed to peculiar characteristics tumor immune microenvironment (TIME).

Язык: Английский

Процитировано

44
Sexual-biased necroinflammation is revealed as a predictor of bevacizumab benefit in glioblastoma DOI Creative Commons
Sara Hiller-Vallina,

Lucía Mondéjar-Ruescas,

Marta Caamaño-Moreno

и другие.

Neuro-Oncology, Год журнала: 2024, Номер 26(7), С. 1213 - 1227

Опубликована: Фев. 27, 2024

Glioblastoma (GBM) is a highly malignant brain tumor that affects men more often than women. In addition, the former shows poorer survival prognosis. To date, reason for this sex-specific aggressiveness remains unclear. Therefore, aim of study to investigate processes explain these sex differences.

Язык: Английский

Процитировано

10
Sex-dependent effects in the aged melanoma tumor microenvironment influence invasion and resistance to targeted therapy DOI
Yash Chhabra, Mitchell E. Fane, Sneha Pramod

и другие.

Cell, Год журнала: 2024, Номер 187(21), С. 6016 - 6034.e25

Опубликована: Сен. 6, 2024

Язык: Английский

Процитировано

8
The Burden of Multiple Myeloma in China: Trends from 1990 to 2021 and Forecasts for 2050 DOI Creative Commons
Xuelin Dou, Guangcai Duan,

You Zhong

и другие.

Cancer Letters, Год журнала: 2025, Номер 611, С. 217440 - 217440

Опубликована: Янв. 2, 2025

Язык: Английский

Процитировано

1
Are sex and gender considered in head and neck cancer clinical studies? DOI Creative Commons
Aurora Gaeta, Marta Tagliabue, Oriana D’Ecclesiis

и другие.

npj Precision Oncology, Год журнала: 2023, Номер 7(1)

Опубликована: Сен. 7, 2023

Abstract We analyzed the inclusion of sex and/or gender (S/G) in Head and Neck Cancer (HNC) clinical studies, through inspecting ClinicalTrials.gov (AACT) mention Human Papilloma Virus (HPV) on a specific subgroup, namely oral cavity, larynx oropharynx. Only 5% HNC studies S/G as planned analytical variable. Proportionally more observational treated an variable than interventional (10% vs 5%, P -value ≤ 0.001), 8% that mentioned involved 100 subjects while 4% less ( 0.001). In randomized protocols, was with sample patients including HPV status < 0.05). Small controlled have lower uncontrolled (4% 10%, respectively among subjects). Significantly greater is observed size subjects. only 18% cavity-larynx-oropharynx studies. Interventional do not regularly account for during study design. Thus, although fundamental, concerning often considered. trials published scientific journals = 0.01) recent 0.002), taken into suggesting increasing awareness its importance. However, need to systematically include design clearly emerges, better highlight sex-related differences disease incidence prognosis best imbue science medicine proper biological cultural differences.

Язык: Английский

Процитировано

17
Treating sex and gender differences as a continuous variable can improve precision cancer treatments DOI Creative Commons
Wei Yang, Joshua B. Rubin

Biology of Sex Differences, Год журнала: 2024, Номер 15(1)

Опубликована: Апрель 15, 2024

Abstract Background The significant sex and gender differences that exist in cancer mechanisms, incidence, survival, have yet to impact clinical practice. One barrier translation is phenotypes cannot be segregated into distinct male versus female categories. Instead, within this convenient but contrived dichotomy, are highly overlapping vary between female- male- skewed extremes. Thus, gender-specific treatments unrealistic, our translational goal should adaptation of treatment the variable effects on targetable pathways. Methods To overcome obstacle, we profiled similarities 8370 transcriptomes 26 different adult 4 pediatric types. We calculated posterior probabilities predicting patient based observed sexes similar samples map transcriptome similarity. Results Transcriptomic index (TI) values were derived from allowed us identify poles with local enrichments for or transcriptomes. TI supported deconvolution measures patient-specific activity gender-biased, It identified gender-skewed extremes mechanistic like cell cycle signaling immunity, precisely positioned each patient’s whole an axis continuously varying phenotypes. Conclusions Cancer type, gender, value provides a novel patient- specific identifier can used realistic gender-adaptations precision planning.

Язык: Английский

Процитировано

6
Influence of donor–recipient sex on engraftment of normal and leukemia stem cells in xenotransplantation DOI Creative Commons
Syed A. Mian,

Linda Ariza‐McNaughton,

Fernando Anjos‐Afonso

и другие.

HemaSphere, Год журнала: 2024, Номер 8(5)

Опубликована: Май 1, 2024

Abstract Immunodeficient mouse models are widely used for the assessment of human normal and leukemic stem cells. Despite advancements over years, reproducibility, as well differences in engraftment cells recipient mice remains to be fully resolved. Here, we various immunodeficient characterize effect donor–recipient sex on healthy Donor demonstrate sex‐specific levels with significant observed lineage output CD34 + hematopoietic progenitor upon xenotransplantation. Intriguingly, female donor display heightened sensitivity mice's gender, influencing their proliferation resulting significantly increased mice. Our study underscores intricate interplay taking place between characteristics, shedding light important considerations future studies, particularly context pre‐clinical research.

Язык: Английский

Процитировано

6